[1] McHutchison JG, Patel K, Pockros P, et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.?J Hepatol. 2006;44(1):88-96. doi:10.1016/j.jhep.2005.09.009 DOI:
10.1016/j.jhep.2005.09.009